Physician

Benjamin Thomas Herms, M.D.

According to 2025 Medicare claims, Benjamin Herms, M.D. (NPI: 1730218876) practices hematology/oncology in the Cincinnati, OH-KY-IN market, with the plurality of this provider's patient population coming from Clermont, OH. This provider's primary affiliated billing organization is ONCOLOGY HEMATOLOGY CARE INC (NPI: 1790778041; TIN: 311106418) and primary practice location at 45245-1898. Herms is affiliated with the Mercy Health Select, LLC (ACO ID: A1215), participating under the MSSP model.

Herms' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 574 traditional Medicare patients, billed 118,899 HCPCS/CPT codes, and received $2,393,153 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,687 prescription claims across 263 beneficiaries totaling $3,555,292 in drug costs, led by Imbruvica (Ibrutinib). 2022 DME data shows 158 claims. Open Payments data shows 12 records totaling $8,333. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,339,066 to $2,393,153. Similarly, Part D prescription costs have risen steadily, from $1,040,980 to $3,555,292. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $10,516 to $7,175.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	650	150,795	$1,339,066
2016	635	272,492	$2,010,775
2017	635	245,284	$2,140,371
2018	647	217,718	$2,186,134
2019	654	210,556	$2,637,530
2020	572	149,752	$2,676,293
2021	574	179,758	$2,994,936
2022	671	184,615	$3,099,123
2023	589	112,416	$2,234,736
2024	574	118,899	$2,393,153

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	298	1,611	$1,040,980
2016	266	1,783	$1,975,303
2017	269	1,651	$2,204,869
2018	271	1,595	$2,445,069
2019	280	1,563	$2,899,798
2020	257	1,519	$2,941,911
2021	240	1,327	$2,613,815
2022	242	1,342	$2,576,031
2023	268	1,466	$2,422,756
2024	263	1,687	$3,555,292

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	64	221	$65,085
2016	60	327	$43,545
2017	54	496	$94,215
2018	70	408	$16,667
2019	61	282	$14,071
2020	N/R	114	$6,424
2021	N/R	99	$6,714
2022	11	158	$9,072
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	246	548	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	231	275	$58
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	109	145	$12
80053	Blood test, comprehensive group of blood chemicals	206	542	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	266	732	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	35	980	$556,998
Ibrance	Palbociclib	25	700	$389,101
Lenalidomide	Lenalidomide	26	728	$329,234
Tukysa	Tucatinib	11	330	$287,565
Calquence	Acalabrutinib Maleate	19	570	$280,822

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	11	$233	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$8,100	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Benjamin Thomas Herms, M.D.?

Tedicare shows public-source Medicare data for Benjamin Thomas Herms, M.D. (NPI 1730218876), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Benjamin Thomas Herms, M.D. have ACO affiliation data?

Benjamin Thomas Herms, M.D. is shown with ACO affiliation data for Mercy Health Select, LLC (MSSP, ACO ID A1215).

What billing organization is linked to Benjamin Thomas Herms, M.D.?

Benjamin Thomas Herms, M.D. is linked to ONCOLOGY HEMATOLOGY CARE INC (billing NPI 1790778041) in the available physician profile data.

Does Benjamin Thomas Herms, M.D. have Open Payments data?

Benjamin Thomas Herms, M.D. has 12 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.